The Lira Pump Trial

NCT02351232 on ClinicalTrials.gov · last registry update 2020-02-12

Finished October 2016, after enrolling 44 people. Primary outcome, as filed: Change in HbA1c. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2/P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Hvidovre University Hospital
Sponsor type: Other
Enrollment: 44
Started: 2015-02
Primary completion: 2016-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Type 1 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.